G63.2 G61.8
Conditions
Interventions
Group 1: type 2 diabetic patients without polyneuropathy
- Collection of anamnestic data
- Use of laboratory data performed in clinical routine (e.g. HbA1c, kidney values)
- Collection of clinical s
Sponsors
Universitätsklinik Jena, Klinik für Neurologie
Eligibility
Sex/Gender
All
Age
40 Years to 85 Years
Inclusion criteria
Inclusion criteria: - Indication/diagnosis: patients with diabetes mellitus type 2 - Age: = 40 years = 85 years - Written consent
Exclusion criteria
Exclusion criteria: - Neuromuscular disease of other cause - History of alcohol abuse - Derailed diabetes (HbA1c > 9%) - Rheumatological disease - Arterial obstructive disease - Active malignant disease - Use of neurotoxic drugs (ongoing/medical history)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the value of nerve ultrasound in diabetic polyneuropathy (compared to the gold standard of electrophysiological measurement). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The prevalence of diabetic polyneuropathy and the prevalence of CIDP in diabetes mellitus will be determined. 2. The value of nerve ultrasound in CIDP patients with diabetes mellitus will be assessed in order to better differentiate one of the most common inflammatory and treatable neuropathies from diabetic polyneuropathy. 3. In order to be able to make prognostic statements, the progression of diabetic polyneuropathy will be estimated using nerve ultrasound. 4. Since changes in the peripheral nerves already take place before the patients become symptomatic, we want to find preclinical parameters in ultrasound and electrophysiology, which can be used as risk factors for the development of diabetic polyneuropathy. | — |
Countries
Germany
Contacts
Public ContactBianka Heiling
Universitätsklinikum Jena, Klinik für Neurologie
Outcome results
None listed